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Genotypic and functional properties of early
infant HIV-1 envelopes
Michael Kishko1, Mohan Somasundaran2, Frank Brewster2, John L Sullivan2,3, Paul R Clapham3 and
Katherine Luzuriaga2,3*
Abstract
Background: Understanding the properties of HIV-1 variants that are transmitted from women to their infants is
crucial to improving strategies to prevent transmission. In this study, 162 full-length envelope (env) clones were
generated from plasma RNA obtained from 5 HIV-1 Clade B infected mother-infant pairs. Following extensive
genotypic and phylogenetic analyses, 35 representative clones were selected for functional studies.
Results: Infant quasispecies were highly homogeneous and generally represented minor maternal variants,
consistent with transmission across a selective bottleneck. Infant clones did not differ from the maternal in env
length, or glycosylation. All infant variants utilized the CCR5 co-receptor, but were not macrophage tropic.
Relatively high levels (IC50 ≥ 100 μg/ml) of autologous maternal plasma IgG were required to neutralize maternal
and infant viruses; however, all infant viruses were neutralized by pooled sera from HIV-1 infected individuals,
implying that they were not inherently neutralization-resistant. All infant viruses were sensitive to the HIV-1 entry
inhibitors Enfuvirtide and soluble CD4; none were resistant to Maraviroc. Sensitivity to human monoclonal
antibodies 4E10, 2F5, b12 and 2G12 varied.
Conclusions: This study provides extensive characterization of the genotypic and functional properties of HIV-1 env
shortly after transmission. We present the first detailed comparisons of the macrophage tropism of infant and
maternal env variants and their sensitivity to Maraviroc, the only CCR5 antagonist approved for therapeutic use.
These findings may have implications for improving approaches to prevent mother-to-child HIV-1 transmission.
Background
Mother-to-child HIV-1 transmission is the primary
mode of pediatric infection. Over 50% of HIV-1 infected
individuals around the world are women in their child-
bearing years [1,2]. In the absence of intervention, more
than a third of the children born to infected mothers
acquire HIV-1 through mother-to-child transmission
(MTCT) [3-5]. This accounts for up to 14% of all HIV-1
transmission [1,5], with 370,000 infants infected in 2009.
MTCT can occur during gestation, at delivery and
through breastfeeding. Seventy-five percent of HIV-1
infected children die by the age of 3 years, accounting
for up to 20% of all HIV-1 related deaths [6,7]; in
resource-limited settings, HIV-1 accounts for one third
of all deaths among children under five [1].
Studies in multiple cohorts, across several clades, have
demonstrated that a marked restriction in the diversity
of founder viruses in blood and plasma is a hallmark of
mucosal HIV-1 infection, including sexual transmission
[8-12] and MTCT [13]. This restricted diversity suggests
either the transmission or post-transmission amplifica-
tion of a single donor variant in the majority of recipi-
ents [3,14-16]. The genetic and biologic determinants of
the transmission bottleneck are largely unknown.
The env glycoprotein (gp160) engages the HIV-1
receptor and co-receptors, mediating virus entry into
cells [17], and is the primary target for neutralizing anti-
bodies. Env is also the most variable HIV-1 gene. We
therefore set out to extensively characterize the geno-
types and phenotypes of full-length env molecular clones
from HIV-1 infected mother-infant pairs. Better under-
standing of the genotypic and functional properties of
transmitted env variants may facilitate the development
of improved strategies to prevent MTCT.
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Results
Phylogeny of envelope sequences
Full-length env genes were amplified from mother and
infant patient plasma HIV-1 RNA (Table 1). At least 10
clones were generated for each subject; 88% of env
clones proved functional, with no significant differences
in functionality between mothers and infants detected
within or across transmission pairs (data not shown). A
total of 162 functional maternal and infant env clones,
each from an independent limiting dilution RT-PCR,
were obtained and sequenced through the V1-V5
regions of the envelopes. A neighbor-joining tree was
constructed by alignment of these nucleotide sequences
(Figure 1A). For one patient (P1031), three clones were
sequenced through V1-V3 only and are not included in
the tree. The resulting tree revealed clear epidemiologi-
cal linkage within each mother-infant pair, with no evi-
dence of cross-pair or other contamination. Maximum
likelihood trees and Highlighter alignments of non-gap
stripped sequences were used to confirm phylogeny and
select representative clones (data not shown).
At least 2 clones were selected from each infant: the clo-
sest to and farthest from the consensus of the subject. In
two cases where the infants were clearly infected with two
maternal variants (P1031 and P1024; Figure 1A), clones
from the major infant variant were selected as above, and
the clone closest to the consensus of the minor infant var-
iant was also included. At least four maternal clones were
selected from each subject to sample the breadth of their
quasispecies. Using Maximum Likelihood Trees, a mater-
nal clone was selected from each of the two branches clo-
sest to the infant, and two additional clones were chosen
from distantly related branches (data not shown). Full-
length gp160 sequences of both DNA strands were
obtained for the selected clones.
Full-length env sequences were obtained for all
selected clones (Figure 1B), and the consensus gp160
sequence was determined for each infant. Of the 13
infant clones selected, four were identical to their
infant’s gp160 consensus. Eight clones differed from the
consensus by two amino acids or less, one differed by
three, and one (P1024 H2) differed by six. For two ran-
domly selected infants (P1189 and P1049), consensus
gp160 sequences generated by SGA were identical to
those obtained by endpoint dilution PCR (data not
shown). Phylogenetic analyses confirmed that all sub-
jects were infected with subtype B.
Visual inspection of phylogenetic trees (Figure 1 and
2) and Highlighter alignments (data not shown) of each
mother-infant pair demonstrated probable transmission
of a single maternal variant to infants P1189, P1049, and
P1046, two variants to infant P1031 and two or three to
infant P1024. Of the variants transmitted to P1024, two
arose from very closely related viruses, or through post-
transmission diversification (Figure 2). The relationship
between maternal and infant quasispecies was further
analyzed based on the paradigm described by Haaland
et al. [18]. The number of amino acids differing between
each infant variant and the most closely related mater-
nal sequence in the V1-V5 region were determined, as
were the number of maternal sequences differing from
an infant variant by less than three amino acids (Table
2). A maternal sequence differing from an infant variant
by less than three amino acids likely gave rise to that
variant. If such sequences represent less than 5% of the
maternal quasispecies, a minor maternal variant was
likely transmitted to the infant [18]. Infant P1024 was
apparently infected with two or three minor variants of
the maternal quasispecies, infant P1049 with a single
major variant, infant P1031 with two minor variants,
while infants P1189 and P1046 each received a single
minor variant (Table 2). Infant sequences were more
homogeneous than maternal, with the mean diversity,
measured by number of base substitutions per site
within each subject ranging from 0.1 to 0.3% among
infants, and 0.6 to 4.6% among mothers (Figure 3).
Table 1 Clinical and laboratory status of study participants
Subjecta Birth
year
Sample
timing
Plasma viral load
(copies/ml)
CD4 CD8 CD4:
CD8
No. of env
clones
No. of pseudo
viruses
ART
status
M1003 0 14158 466 932 0.50 12 4 None
P1189 1994 31 311538 2872 1975 1.45 10 2 None
M1002 28 ND 872 1225 0.71 25 5 None
P1031 1992 54 685169 2147 927 2.32 11 3 None
M1001 2 26000 534 726 0.74 19 4 None
P1024 1990 51 750000 3312 4504 0.74 11 2 None
M1007 -8 ND 870 1176 0.74 22 4 ZDV
P1046 1995 66 1229730 2573 1693 1.52 22 4 ZDV*
M1006 -33 260541 134 403 0.33 20 5 ZDV
P1049 1999 30 647919 ND ND ND 10 2 ZDV*
aM, Mother; P, Infant. ZDV, Zidovudine administered to mother or infant to prevent MTCT. ND, Not determined. Timing of samples used for cloning in days after
delivery; negative numbers indicate days before delivery.
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Figure 1 Evolutionary relationships of HIV-1 env clones. Evolutionary history was inferred using the Neighbor-Joining method. (A) V1-V5
nucleotide sequences of cloned env and subtype reference sequences. Filled triangle = infant, empty circle = maternal sequence. (B) Full length
gp160 nucleotide sequences. M = maternal, P = infant. The percentage of replicate trees in which the associated sequences clustered together
>70% of the time in the bootstrap test (1000 replicates) are shown to the left of branches in (B). The evolutionary distances were computed
using the Kimura 2-parameter method. All positions containing gaps and missing data were eliminated from the dataset. Horizontal scale bars
represent (A) 5%, or (B) 1% genetic distance.
Kishko et al. Retrovirology 2011, 8:67
http://www.retrovirology.com/content/8/1/67
Page 3 of 14
The consensus sequence of clones amplified shortly
following transmission from a subject infected with a sin-
gle donor variant represents the sequence of the trans-
mitted/founder virus [18]. We compared maternal gp160
sequences to the consensus of each infant variant to
determine how closely clones selected for their similarity
to infant env approached the transmitted/founder
sequence. Maternal clones most closely related to their
infants were; M1003 P16 which differed from the infant
consensus by three amino acid substitutions, M1001 J7
which differed by four amino acids substitutions, M1007
T1 which differed by three amino acids, M1006 X1
which differed by three substitutions, and M1002 J4
which differed by 15 amino acids. No maternal sequence
was identical to the consensus of an infant variant. We
then compared the maternal sequences to each individual
sequence amplified from her infant and did not detect
any maternal sequence identical to any infant sequence.
Env V1-V5 length, glycosylation and co-receptor tropism
Since env length and glycosylation have been reported to
correlate with mucosal transmission, including MTCT [15],
we investigated these factors in our panel. In pairs M1001-
P1024 and M1007-P1046, the median V1-V5 length of
infant sequences was greater than maternal, while in pairs
M1002-P1031, M1006-P1049, and M1003-P1189, the med-
ians were similar (Table 3). The median number of V1-V5
PNGS was smaller in the infant sequences than in the
mother’s for pair M1002-P1031, greater for pair M1001-
P1024, and equal in pairs M1007-P1046, M1006-P1049 and
M1003-P1189 (Table 3). Statistical analysis did not indicate
significant within-pair differences in the mean env length or
glycosylation between maternal and infant clones. The V3
loop charge and glycosylation are predictive of co-receptor
tropism [19,20]. Examination of charge and glycosylation of
the V3 loops of our env clones did not reveal any CXCR4
(X4) tropic variants in our panel and only one mother
gaps G C A T 
Figure 2 Highlighter analysis of infant P1024 V1-V5 sequences.
The subject quasispecies consists of three variants. Sequences
belonging to the same variant are indicated by colored arrows. Pink
and blue variants arose from transmission of two very closely
related maternal viruses, or by post-transmission diversification. The
brown variant arose from transmission of a distinct maternal virus.
Table 2 Relationship of maternal and infant V1-V5
sequences
Infant Sequences
analyzeda
Differencesb Less than 3
differencesc
P1189 12 1 1
P1031 25 3 0
11 0
P1024 19 5 0
3 0
3 0
P1046 22 1 1
P1049 20 2 4
aNumber of maternal sequences analyzed.
bNumber of amino acids that differ between an infant variant consensus
sequence and the most closely related maternal sequence.
cNumber of maternal sequences differing from the infant variant consensus
by less than 3 amino acids.
0 1 2 3 4 5
P1049
M1006
P1046
M1007
P1024
M1001
P1031
M1002
P1189
M1003
Percent base substitutions per site
within each subject
Figure 3 Infant quasispecies are more homogeneous than
maternal. The percent of base substitutions per site over the V1-V5
region for each subject were computed using the Kimura 2-
parameter method in the MEGA4 software program.
Kishko et al. Retrovirology 2011, 8:67
http://www.retrovirology.com/content/8/1/67
Page 4 of 14
(M1006), was predicted to harbor CCR5/CXCR4 dual tro-
pic variants. Only CCR5 (R5) tropic maternal variants were
transmitted to the infants (Table 3).
Receptor and co-receptor requirements
The in-silico R5 tropism predictions were confirmed in
vitro by comparing titers on the TZMbl and HIJ cell
lines. TZMbl express both the CCR5 and CXCR4 co-
receptors, while HIJ express CXCR4 but not CCR5 [21].
Pseudoviruses expressing the X4 tropic NL4.3 env and
the R5 tropic SF162 env were used as controls; NL4.3
env infected both cell lines while SF162 env infected
only TZMbl. All maternal and infant clones achieved
high titers on TZMbl, but only one maternal clone
(M1006 P1) infected both cell lines (Figure 4A).
The receptor (CD4) and co-receptor (CCR5) use of
representative maternal and infant env clones (n = 35, Fig-
ure 1B) was then analyzed in depth. Pseudoviruses expres-
sing these env were generated and titered on TZMbl cells
(Figure 4A), and on additional HeLa cell lines expressing
varying levels of CD4 and CCR5 [21] (Figure 4B-E). Infant
viruses infected all cell lines tested. When pairwise com-
parisons were made, there was no significant difference
between the mean infant and maternal titers on any cell
line. All clones achieved highest titers on TZMbl cells,
which express the highest levels of CD4 and CCR5. Titers
decreased with decreasing levels of CD4 (Figure 4B verses
D) or CCR5 (Figure 4B verses C, and D verses E), but
were more sensitive to changes in CD4.
Replication in primary macrophages and PBL
We used two different approaches to evaluate the ability of
maternal and infant viruses to replicate in primary macro-
phages. First, we investigated the ability of pseudoviruses
expressing the env clones to mediate infection of primary
macrophage cultures in a single round infection. All infant
viruses exhibited low or no infectivity in monocyte derived
macrophages (MDM); similarly, only a single maternal
clone (M1002 G1) attained a high level of infection as
compared to the non-macrophage tropic and highly
macrophage tropic controls (Figure 5). Macrophage infec-
tivity was further investigated by infecting matched donor
MDM and PBLs with EGFP-tagged recombinant env
clones from two randomly selected mother-infant pairs
(Table 4). No fluorescence was detected in macrophage
cultures throughout two weeks of infection while high
levels of fluorescence were detected in each PBL infection.
Measurement of HIV-1 p24 in the supernatants collected
from cultures over the course of infection showed a steady
decline from the input levels of p24 in macrophage infec-
tions, while PBL infections showed an increase. Altogether,
these data demonstrate robust replication in PBL but uni-
formly poor replication in macrophages.
Sensitivity of envelope clones to neutralization by
autologous maternal plasma
We assayed at least three clones from each mother-
infant pair. Relatively high levels (≥ 100 μg/ml) of auto-
logous maternal plasma IgG were required to neutralize
maternal and infant viruses (Figure 6A). Statistical ana-
lysis did not indicate significant within-pair differences
in the susceptibility of maternal and infant clones to
neutralization by autologous maternal IgG.
Sensitivity of envelope clones to neutralization by
monoclonal antibodies and pooled seropositive plasma
Using a standardized assay [22,23], we tested the neutra-
lization sensitivity profile of our pseudoviruses to a
Table 3 Genotypic analyses of V1-V5 sequences
Subjecta V1-V5 lengthb* V1-V5 PNGSc* V3 charge V3 glycan V3 crown motifd Tropisme
M1003 335 24 (23-25) +3 Yes APGR R5
P1189 335 25 (25-25) +3 Yes APGR R5
M1002 329 (329-333) 21 (20-24) +3 Yes GPGR R5
P1031 329 (329-330) 19 (19-20) +3 Yes GPGR R5
M1001 345 (342-347) 23 (22-25) +2 Yes GPGG, GPGR R5
P1024 346 (345-346) 24 (23-24) +2 Yes GPGR R5
M1007 328 (328-335) 23 (22-24) +4 Yes GPGR R5
P1046 335 23 (21-23) +4 Yes GPGR R5
M1006 332 (320-349) 24 (17-26) +3 +4 +5 Yes, No QPGR, QPGG R5, R5/X4
P1049 332 24 (24-24) +3 Yes QPGR R5
aM, Mother; P, Infant.
bMedian length of the env V1-V5 region as median (min-max).
cMedian number of potential N-linked glycosylation sites in the V1-V5 region as median (min-max).
dDominant variant presented first.
eTropism determined in-vitro. R5, CCR5; R5/X4, CCR5/CXCR4.
*p > 0.05. Pairwise differences between maternal and infant values were evaluated using Mixed Model ANOVA with mother-infant pairs included as random
effects.
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Figure 4 Receptor and co-receptor requirements of cloned env. Pseudoviruses expressing cloned env were titered on HeLa cell lines
engineered to express various levels of CD4 and CCR5. To normalize between different pseudovirus preparations, titers are expressed as a ratio
of the titer on the cell line divided by the titer on TZMbl cells. (A) TZMbl, (B) JC37, (C) JC10, (D) RC49, (E) RC23. Results are an average of 3
independent experiments performed in duplicate. Average number of receptor and co-receptor molecules per cell as reported by Platt et al [21]
is inset in the charts. Filled triangle = infant, empty circle = maternal. Pairwise statistical analysis performed using the Mixed Model ANOVA with
mother-infant pairings included as random effects indicated that mean maternal and infant titers did not vary significantly across pairs.
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panel of well-established human NAbs, including b12
(CD4 binding site), 2G12 (carbohydrate-dependent) and
the gp41 Membrane Proximal External Repeat (MPER)
specific NAbs 2F5 and 4E10 (Figure 6B). No infant or
maternal clone was resistant to 2F5. Only one clone was
resistant to 4E10 (P1046 J1) and expressed the rare,
resistance conferring, natural polymorphism F673L
[24,25]. All clones from three infants were resistant to
20 μg of 2G12 and exhibited mutations eliminating one
of five PNGS implicated in 2G12 binding [26]. In infant
P1024, the mutation was N386D, in P1049 it was
N392K, and in P1046 it was T292I. Most maternal
clones from these pairs exhibited similar levels of 2G12
resistance, and displayed the corresponding mutations.
Infants P1031, P1046 and P1049 had some clones resis-
tant to 20 μg of b12, but each had one sensitive clone.
A similar pattern of sensitive and resistant clones was
seen in the corresponding mothers. When pairwise ana-
lyses were performed, we did not detect any trends for
differential neutralization sensitivity between infant and
maternal variants.
The neutralization sensitivity of the pseudoviruses to
pooled heterologous plasma with high NAb activity was
next determined (Figure 6C). Sensitivity varied over a 4-
fold range within mother-infant pairs, but all infant and
maternal viruses were sensitive to neutralization at
plasma reciprocal dilutions ranging from 109 to 1588.
Pairwise analysis failed to detect any trends for within-
pairs differences in neutralization sensitivity to this
reagent.
Sensitivity of infant envelope clones to HIV-1 entry
inhibitors
The sensitivity of infant clones to three HIV-1 entry
inhibitors was evaluated (Figure 6 and data not shown).
The inhibitors used were sCD4, T20 (fusion inhibitor)
and Maraviroc (CCR5 antagonist). Since Maraviroc is a
non-competitive inhibitor, we determined the MPI of
our clones by this inhibitor. All clones were inhibited by
>99% at concentrations exceeding 400 nM, indicating
that none were resistant [27,28]. The NL4.3 env control
exhibited a MPI of <2% (data not shown).
Infant clones were sensitive to T20 and sCD4, exhibit-
ing IC50 ranges similar to the maternal. Mean T20 IC50
for infant clones was 0.23 μg/ml and 0.24 μg/ml for
maternal. Soluble CD4 exhibited a mean IC50 of 7.24
μg/ml for infants and 6.43 μg/ml for mothers. No signif-
icant within-pair differences in sensitivity to these inhi-
bitors were observed between maternal and infant
viruses.
Discussion
We generated full-length viable env clones from 5
mother-infant pairs and extensively characterized their
V1-V5 genotypes and phylogeny. Phylogenetic analyses
showed that infant sequences were more homogeneous
than maternal viral sequences. The highest sequence
diversity seen in the infants, 0.3%, fits well with the
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Figure 5 Macrophage infectivity. Pseudoviruses expressing cloned
envelopes were titered on primary macrophage cultures.
Macrophage infectivity is expressed as the percentage of the TZMbl
titer achieved on macrophages. Data is representative of three
independent assays performed in duplicate. Filled triangle = infant,
empty circle = maternal. Clone M1002 G1 is highlighted red. Cont =
Controls [42], see inset key: (macrophage tropic) NA20 B59, NA420
B33 and JRFL, (non-macrophage topic) JRCSF, NA420 LN40 and
NA20 LN8.
Table 4 Maternal and infant viruses replicate well in PBL
but poorly in MDM
Fluorescence p24 ELISAa
Clone ID MDM PBL MDM PBL
M1003 P16 No Yes No Yes
M1003 D6 No Yes No Yes
M1003 O1 No Yes No Yes
M1003 Q4 No Yes No Yes
P1189 F3 No Yes No No
M-1007 Z8 No Yes No Yes
M-1007 Q8 No Yes No Yes
M-1007 Y7 No Yes No Yes
P-1046 W2 No Yes No Yes
P-1046 C4 No Yes No Yes
P-1046 J1 No Yes No Yes
P-1046 K1 No Yes No Yes
aIncrease in p24 antigen levels above input.
Infections with clones from the M1003-P1189 transmission pair were carried
out at an MOI of 0.01, while those from the transmission pair M1007-P1046
were done at an MOI of 0.001.
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model of Keele et al. [9], which indicates that the maxi-
mum diversity expected within an individual shortly
after infection with a single virus is 0.6%. Of the 8 trans-
mitted/founder variants identified in the infants of our
cohort, seven represented minor variants of the mater-
nal quasispecies at the time of sampling, which was
within a few weeks of transmission. These data support
previous findings [13,14,29] suggesting a selective bottle-
neck during MTCT.
Consensus gp160 endpoint dilution sequences from
two randomly selected infants were identical to those
obtained by SGA. These results are compatible with a
recent report that standard PCR and SGA provide simi-
lar measures of viral diversity when sufficient templates
are analyzed [30].
Several groups have reported shorter hypervariable
regions and fewer N-linked glycosylation sites in Clade
C sexually (reviewed [31]) or maternally [32] transmitted
viruses. Our data on Clade B viruses are compatible
with others’ work that did not find altered env length or
glycosylation site number in transmitted Clade B viruses
[33].
All infant clones were R5 tropic, consistent with
numerous prior reports [34-36]. Intrapartum transmis-
sion of HIV-1 is hypothesized to occur across the
mucosa, although the exact mechanisms have not been
determined (reviewed [37,38]). Efficient HIV-1 infection
usually requires the expression of relatively high levels
of the CD4 receptor and CCR5 co-receptor on the sur-
face of target cells [21,39]. However, levels of CD4 and
CCR5 on mucosal and submucosal cell subsets can be
much lower than on CD4+ memory T cells [40]. Titra-
tion on cell lines expressing different levels of CD4 and
CCR5 demonstrated efficient infection of cells with
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Figure 6 Sensitivity of maternal and infant env to neutralization or inhibition. The sensitivity of infant and maternal clones to (A)
autologous maternal IgG, (B) NAbs, (C) pooled seropositive plasma and (D) entry inhibitors was determined using pseudovirus infection of
TZMbl cells. (A) Neutralization IC50 of maternal and infant env clones. Lines indicate maximum concentration of IgG. (B-D) Values are an average
of two different pseudovirus stocks run in the same experiment. Solid lines indicate infant and maternal means. Dotted lines in (B) indicate
maximum concentration of NAb used. Filled triangle = infant, empty circle = maternal. Pairwise statistical analysis performed using the Mixed
Model ANOVA with mother-infant pairings included as random effects indicated that mean maternal and infant IC50 did not vary significantly
across pairs.
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variable levels of these molecules. This finding is sup-
ported by our failure to observe any systematic differ-
ences in the sensitivity of maternal and infant env to
inhibition by sCD4 or CCR5 inhibitors. It is also in
agreement with a recent report that sexual HIV-1 trans-
mission does not appear to select for viruses that can
preferentially utilize lower levels of CD4 or CCR5 [39].
CCR5 co-receptor usage has traditionally been equated
with macrophage-tropism. Peters et al. have recently
clarified that not all R5 viruses are macrophage-tropic
(reviewed [41]). Only 1 of 35 plasma-derived env clones
achieved greater than 1% of their TZMbl titers on MDM.
Our results are in agreement with prior data [42] demon-
strating that peripheral blood viruses frequently exhibit
low levels of macrophage infectivity, and that sexually
transmitted R5 tropic variants replicate poorly in macro-
phages [43,44]. Finally, these findings support recent
models of HIV-1 transmission, which suggest that cell
subtypes other than macrophages are the first to encoun-
ter HIV-1 during mucosal transmission [44,45].
We screened our clones to determine their sensitivity
to neutralization by a panel of well-characterized mono-
clonal Nabs. Sensitivity to these NAbs varied both
between and within mother-infant pairs. Clones were
uniformly sensitive to 2F5. Only one clone (from infant
P1046) was resistant to 4E10; this clone exhibited the
F673L natural polymorphism associated with resistance
to this Nab [24]. All clones with 2G12 resistance corre-
lated with loss of one of five PNGS that make up the
2G12 epitope.
At least two groups have reported that infant env
clones are relatively resistant to neutralization by autolo-
gous maternal plasma [15,46]. Relatively high levels
(IC50 ≥ 100 μg/ml) of autologous maternal plasma IgG
were required to neutralize maternal and infant viruses;
however, all infant viruses were neutralized by pooled
sera from HIV-1 infected individuals, implying that they
were not inherently neutralization-resistant.
CCR5 antagonists are a potent new class of entry inhi-
bitors. Since only R5 variants are vertically transmitted,
CCR5 antagonists may be highly relevant to blocking
MTCT; however their effectiveness against infant iso-
lates has not been well characterized, and partial resis-
tance to CCR5 antagonists in a treatment-naïve
individual has been reported [28]. All env clones in our
panel were sensitive to Maraviroc. All infant clones
were also sensitive to T20 and sCD4, and no significant
differences in sensitivity were seen between maternal
and infant viruses. The latter is in contrast with data
from Keele et al. [9], who demonstrated significantly
higher IC50 values for T1249, a fusion inhibitor with a
mechanism of action similar to T20, among viruses
from acutely infected as compared to chronically
infected subjects.
Conclusions
Although we have a relatively small sized patient cohort,
the results of our extensive genotypic and phenotypic
studies confirm that clade B MTCT occurs across a
selective bottleneck, and that neither env length nor gly-
cosylation appear to play a role in this selection. Utiliza-
tion of low receptor and co-receptor levels for entry
likewise does not appear to play a major role in the
selective bottleneck during vertical transmission of HIV-
1 clade B. Most intriguingly, R5 tropic maternal and
infant env exhibited poor macrophage infectivity. Rela-
tively high levels (IC50 ≥ 100 μg/ml) of autologous
maternal plasma IgG were required to neutralize mater-
nal and infant viruses. Maternal and infant clones were
equally sensitive to pooled heterologous plasma, imply-
ing that inherent neutralization resistance is unlikely to
be a major factor controlling the selective bottleneck.
Infant clones were variably sensitive to neutralization by
monoclonal antibodies but uniformly sensitive to HIV-1
entry inhibitors. Together, our findings provide further
insight into the selective pressures influencing the
genetic bottleneck during vertical transmission of HIV-1
and may help inform the future development of thera-
pies to prevent MTCT.
Materials and methods
Study population
Plasma samples were obtained from 5 HIV-1 clade B
infected women and their infants (Table 1). Maternal
samples were obtained at or within a month of delivery.
None of the mothers exhibited opportunistic infections
or AIDS-defining illnesses. All five infants were infected
at delivery, based on standard definitions [5]. Most
intrapartum transmission is thought to occur across the
mucosa although the exact mechanisms have not been
determined (reviewed [37,38]). None of the infants were
breastfed. Infant samples were obtained within 2 months
of delivery and represent the first time point at which
HIV-1 was detected in the infants by viral isolation or
the detection of nucleic acids.
PCR amplification and generation of functional envelope
(gp160) clones via endpoint dilution
Viral RNA was extracted from 50-200 μl of plasma
using the Roche High Pure Viral RNA Kit (Roche Phar-
maceuticals, Basel, Switzerland). Eluted RNA was treated
with 1 μl of RNasin Plus RNase inhibitor (Promega
Biosciences, San Luis Obispo, CA), then aliquoted and
stored at -80°C. Full-length HIV-1 gp160 was amplified
directly from the viral RNA by endpoint dilution nested
RT-PCR. To identify the endpoint dilutions, RT-PCR
was performed in octuplet on two fold serial dilutions of
each viral RNA extract until a dilution was reached
where not more than three of eight wells showed
Kishko et al. Retrovirology 2011, 8:67
http://www.retrovirology.com/content/8/1/67
Page 9 of 14
product. Outer and inner primer pairs were the same as
reported by Wei et al. [47]. RT-PCR was performed
using the Superscript One Step RT-PCR for Long Tem-
plates kit (Invitrogen Life Technologies, Carlsbad, CA).
Conditions for the outer PCR were as follows: 45°C for
30 min, 94°C for 2 min, 40 cycles of 94°C for 15 sec, 52°
C for 30 sec, 68°C for 3 min, with a final extension at
72°C for 10 min. Inner PCR was performed using the
Platinum Taq DNA Polymerase HighFidelity kit (Invi-
trogen Life Technologies, Carlsbad, CA). Conditions for
the inner PCR were as follows: 94°C for 2 min, 40 cycles
of 94°C for 15 sec, 55°C for 30 sec, 68°C for 3 min, with
a final extension at 72°C for 10 min. The ~3 kb env
amplicons were sub-cloned into the pcDNA3.1/V5-His
TOPO TA vector (Invitrogen Life Technologies, Carls-
bad, CA) using the manufacturer’s instructions. Colonies
containing full length inserts in the correct orientation
were identified by a PCR screen; their functionality was
determined using syncytia as a readout by the addition
of HeLa cells expressing CD4 and CCR5 (TZMbl a.k.a.
JC53BL [21,48]) to monolayers of 293T cells [49] trans-
fected with the molecularly cloned env [50]. At least 10
functional env clones were obtained from each subject,
with each clone originating from an independent end-
point dilution PCR.
Single genome amplification (SGA)
SGA was performed as described by Salazar-Gonzalez et
al. [10]. Briefly, viral RNA extracted as above was
reverse transcribed to single-stranded cDNA using pri-
mer OFM1. The cDNA was diluted in 96 well plates
such that less than 30% of the reactions yielded ampli-
fied product. Nested PCR was then carried out using
primers Vif1 and OFM19 for the outer step, and EnvA
and EnvN for the inner. All correctly sized products
were purified and sequenced.
DNA sequencing, phylogenetic analysis and clone
selection
The V1-V5 regions of all viable molecular env clones
were sequenced using BigDye Terminator chemistry.
Sequences were assembled using the Vector NTI soft-
ware (Invitrogen Life Technologies, Carlsbad, CA). Env
sequences from each subject were aligned using Clus-
talW in the software package BioEdit http://www.mbio.
ncsu.edu/BioEdit/BioEdit.html, and trees were con-
structed using the neighbor joining method [51] imple-
mented in Mega http://www.megasoftware.net using
Kimura’s correction [52] and 1000 iterations of Boot-
strap analysis, and the maximum likelihood method
with 500 iterations of Bootstrap analysis implemented in
PhyML http://www.hiv.lanl.gov. Phylogeny was con-
firmed using the Highlighter software program http://
www.hiv.lanl.gov. Potential N-Linked glycosylation sites
(PNGS) were identified using the N-Glycosite program
http://www.hiv.lanl.gov. The V3 loop charge was deter-
mined by comparing the number of positively charged
(Aspartic Acid and Glutamic Acid) to negatively charged
(Lysine and Arginine) amino acid residues.
Pseudovirus production and titration
Pseudoviruses were made by co-transfecting exponentially
dividing 293T cells with a 1:2 ratio of env and pSG3Δenv
backbone (NIH AIDS Research and Reference Reagent Pro-
gram [47,53]) using Polyethylenimine (Polysciences, War-
rington, PA) as the transfection reagent. Pseudoviral titers
were determined using single round infection of TZMbl
cells essentially as described [23] except that b-galactosidase
staining rather than luminescence was used as the readout.
Cells developed using the b-galactosidase readout were
counted on an automated ELISPOT reader (See Additional
File 1; Supplemental Methods). The titers were expressed
as spot forming units per ml (sfu/ml). Assays utilizing lumi-
nescence gave results very similar to those determined by
using b-galactosidase (data not shown). Titrations were per-
formed at least twice for each pseudovirus.
Construction of replication competent fluorescently
tagged HIV-1
A fluorescently tagged, replication competent HIV-1 back-
bone was obtained from Dr. Matthias Dittmar (Centre for
Infectious Disease, Institute of Cell and Molecular Science,
Barts and The London School of Medicine and Dentistry).
Plasmids encoding selected infant and maternal env in this
backbone were generated as described [54]. Briefly, we
used the plasmid TN6GΔ, which encodes the full length
NL4.3 HIV-1 clone with the nef gene replaced by EGFP
and has unique restriction sites (BstEII and NcoI) in the
env gene available for inserting heterologous env. The
complementary restriction sites were introduced into
selected infant and maternal env clones and used for direc-
tional sub-cloning into TN6GΔ. Live, fluorescently tagged
virus was produced using essentially the same protocol as
for the pseudovirus described above.
Cell line, macrophage, and peripheral blood lymphocyte
(PBL) titrations and infections
Receptor and co-receptor requirements of pseudoviruses
were determined by titration on HeLa cells engineered
to express various levels of the CD4 receptor and CCR5
and CXCR4 co-receptors [21]. In silico predicted CCR5
tropism was confirmed by titration on the HIJ HeLa cell
line, which expresses CD4 and CXCR4 but no CCR5
[21], using pseudoviruses expressing the CXCR4 tropic
NL4.3 env [55] and the CCR5 tropic SF162 env (NIH
AIDS Research and Reference Reagent Program Catalog
# 10463) as controls. Titrations were performed as
described [50] utilizing anti-p24 immunostaining as the
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infectivity readout. To determine macrophage infectivity,
elutriated monocytes were re-suspended in medium
containing macrophage colony stimulating factor and
cultured for seven days before use for pseudoviral titra-
tions essentially as described [50]. Each pseudovirus was
tested in duplicate in 3 independent assays. To normal-
ize between different pseudoviral preparations, all titers
are expressed as a ratio of the titer on the cell line or
macrophage culture divided by the titer on TZMbl cells.
For infection of PBLs, fresh PBLs were maintained in
RPMI 1640 medium supplemented with 10% FBS, sti-
mulated with phytohemagglutinin (5 μg/ml) for 2 days,
and interleukin-2 (10 U/ml) for a further 2 days prior to
infection. PBLs were infected with live virus at an MOI
of 0.01 or 0.001 as indicated (based on TZMbl or PBL
titers as appropriate) and carried for seven days before
being read for HIV-1 positive cells by anti-p24 immu-
nostaining or flow cytometry.
Neutralization and inhibition assays
Neutralization and inhibition assays using human mono-
clonal antibodies, pooled HIV-positive patient sera,
autologous maternal plasma, or HIV-1 entry inhibitors
were performed as previously described [22,23,56-58],
using 200 sfu of pseudovirus to infect TZMbl cells, with
residual infection measured using the b-galactosidase
readout. To determine the activity of CCR5 antagonists,
the assay was modified such that cell monolayers were
incubated with serial dilutions of the inhibitors for one
hour before the addition of virus. Following the addition
of virus, plates were incubated overnight and the media
was replaced with fresh un-supplemented media. Pseu-
doviral stocks expressing well-characterized env from
the NIH AIDS Research and Reference Reagent Program
Standard Reference Panels of Subtype B or C HIV-1 Env
Clones [22,56,57] were used in every experiment and
showed low intra-assay variation, and values similar to
those reported [56,57] (data not shown). Monoclonal
NAbs b12, 2G12, 4E5, and 2F5 were obtained from the
NIH AIDS Research and Reference Reagent Program; an
additional aliquot of b12 was generously provided by
Dr. Dennis Burton (Scripps Research Institute). The
maximum b12 and 2G12 antibody concentration used
in neutralization assays was 20 μg/ml, while 4E10 and
2F5 were used at 50 μg/ml. HIV-1 entry inhibitors solu-
ble CD4 (sCD4, Progenics Pharmaceuticals, Tarrytown,
NY), Enfuvirtide (T20, Roche, Palo Alto, CA) and Mara-
viroc (obtained through the NIH AIDS Research and
Reference Reagent Program) were also evaluated in
these assays. As Maraviroc is a non-competitive inhibi-
tor, resistance was determined by changes in the maxi-
mal percent inhibition (MPI) [59]. The MPI of our
clones was determined by observing plateaus in the inhi-
bition curves [59] at saturating concentrations of Mara-
viroc (up to 4000 nM) [28,59]. All plasma was heat
inactivated at 56°C for 30 minutes before use. Sero-
negative plasma was used as a negative control and
showed no neutralization activity at 1:15 dilution. Pseu-
dovirus expressing murine leukemia virus (MLV) env
was used as a non-specific neutralization control and
generally failed to be inhibited by the highest concentra-
tion of plasma used. Since we have previously observed
non-specific neutralization of the MLV control and
available plasma volumes were limited, we used purified
Immunoglobulin G (IgG) in our autologous neutraliza-
tion assays (see below). For all antibodies and inhibitors,
the 50% inhibitory concentration (IC50) relative to
untreated control infections was determined from plots
generated using the sigmoidal fit function of the Origi-
nPro 7.5 SRO v7 software package [60] (See Additional
File 1; Supplemental Methods).
Autologous neutralization using purified IgG
IgG was purified from plasmas using the Nab Protein
Spin Kit (Thermo Scientific, Rockford, IL) according to
the manufacturer’s protocol. Elution fractions one and
two were pooled and dialyzed in culture media using
the Slide-A-Lyzer Dialysis Kit, 10 K MWCO (Pierce
Biotechnology, Rockford, IL). The amount of IgG in
the dialyzed extracts and the original maternal plasma
was quantified using the Human IgG ELISA Kit (Zep-
toMetrix Corporation, Baffalo, NY). Autologous neu-
tralizations were set up at an initial IgG concentration
of 0.5 mg/ml.
Statistical analyses
Pairwise differences between maternal and infant values
were evaluated using Mixed Model ANOVA [61] with
mother-infant pairs included as random effects. The
analyses were performed using the Proc Mixed proce-
dure [62] in the SAS statistical Software package (SAS
Inc, NC, USA). Significance was reported when p ≤ 0.05.
Nucleotide sequence accession numbers
Nucleotide sequence accession numbers are available
under [GenBank: HM368224 - HM368258].
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Additional material
Additional file 1: Supplemental Methods. Detailed methodology for
the PCR screen, b-galactosidase readout and 50% inhibitory
concentration calculations.
Acknowledgements and Funding
We wish to acknowledge the study participants and their families. We
gratefully acknowledge the technical assistance provided by Kristina McNeal,
Robin Brody, John Latino, and Linda Lambrecht. We thank Margaret
McManus and Dr. Stephen Baker for statistical analyses, Wanda DePasquale
for manuscript preparation, and Paul Peters for advice on assay adaptation.
We thank the NIH AIDS Research and Reference Reagent Program, Dr.
Dennis Burton of The Scripps Research Institute, Roche Palo Alto, and Dr.
Matthias Dittmar of Barts and The London School of Medicine and Dentistry
for the reagents that they generously provided.
This work was supported by the Elizabeth Glaser Pediatric AIDS Foundation,
the Campbell Foundation, the UMMS CFAR Clinical and Virology Cores (NIH
P30 AI42845), the International Maternal Pediatric Adolescent AIDS Clinical
Trials Group, and National Institutes of Health grants AI32391 and HD01489
to K. L., and P01 AI082274, MH064408 and HD49273 for P.C. Overall support
for the International Maternal Pediatric Adolescent AIDS Clinical Trials Group
(IMPAACT) was provided by the National Institute of Allergy and Infectious
Diseases (NIAID) (U01 AI068632), the Eunice Kennedy Shriver National
Institute of Child Health and Human Development (NICHD), and the
National Institute of Mental Health (NIMH) (AI068632). The content is solely
the responsibility of the authors and does not necessarily represent the
official views of the NIH.
Author details
1Graduate School of Biomedical Sciences, University of Massachusetts
Medical School, Worcester, MA, USA. 2Department of Pediatrics, University of
Massachusetts Medical School, Worcester, MA, USA. 3Program in Molecular
Medicine, University of Massachusetts Medical School, Worcester, MA, USA.
Authors’ contributions
MK, FB, MS, PC, KL conceived and designed experiments. MK and FB
performed the experiments. MK, FB, MS, PC and KL analyzed the data. PC,
KL, and JLS contributed samples and reagents. MK, MS and KL wrote the
manuscript. All authors read and approved the manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 10 May 2011 Accepted: 15 August 2011
Published: 15 August 2011
References
1. UNAIDS Report on the Global AIDS Epidemic 2010. Joint United Nations
Programme on HIV/AIDS (UNAIDS) [http://www.unaids.org/globalreport/
default.htm].
2. Quinn TC, Overbaugh J: HIV/AIDS in women: an expanding epidemic.
Science 2005, 308:1582-1583.
3. Ahmad N: The vertical transmission of human immunodeficiency virus
type 1: molecular and biological properties of the virus. Crit Rev Clin Lab
Sci 2005, 42:1-34.
4. Luzuriaga K: Mother-to-child transmission of HIV: a global perspective.
Curr Infect Dis Rep 2007, 9:511-517.
5. Luzuriaga K, Sullivan JL: Pediatric HIV-1 infection: advances and remaining
challenges. AIDS Rev 2002, 4:21-26.
6. Ahmad N, Baroudy BM, Baker RC, Chappey C: Genetic analysis of human
immunodeficiency virus type 1 envelope V3 region isolates from
mothers and infants after perinatal transmission. J Virol 1995,
69:1001-1012.
7. Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F:
Mortality of infected and uninfected infants born to HIV-infected
mothers in Africa: a pooled analysis. Lancet 2004, 364:1236-1243.
8. Goonetilleke N, Liu MK, Salazar-Gonzalez JF, Ferrari G, Giorgi E, Ganusov VV,
Keele BF, Learn GH, Turnbull EL, Salazar MG, Weinhold KJ, Moore S,
Letvin N, Haynes BF, Cohen MS, Hraber P, Bhattacharya T, Borrow P,
Perelson AS, Hahn BH, Shaw GM, Korber BT, McMichael AJ: The first T cell
response to transmitted/founder virus contributes to the control of
acute viremia in HIV-1 infection. J Exp Med 2009, 206:1253-1272.
9. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG,
Sun C, Grayson T, Wang S, Li H, Wei X, Jiang C, Kirchherr JL, Gao F,
Anderson JA, Ping LH, Swanstrom R, Tomaras GD, Blattner WA, Goepfert PA,
Kilby JM, Saag MS, Delwart EL, Busch MP, Cohen MS, Montefiori DC,
Haynes BF, Gaschen B, Athreya GS, Lee HY: Identification and
characterization of transmitted and early founder virus envelopes in
primary HIV-1 infection. Proc Natl Acad Sci USA 2008, 105:7552-7557.
10. Salazar-Gonzalez JF, Bailes E, Pham KT, Salazar MG, Guffey MB, Keele BF,
Derdeyn CA, Farmer P, Hunter E, Allen S, Manigart O, Mulenga J,
Anderson JA, Swanstrom R, Haynes BF, Athreya GS, Korber BT, Sharp PM,
Shaw GM, Hahn BH: Deciphering human immunodeficiency virus type 1
transmission and early envelope diversification by single-genome
amplification and sequencing. J Virol 2008, 82:3952-3970.
11. Zhang LQ, MacKenzie P, Cleland A, Holmes EC, Brown AJ, Simmonds P:
Selection for specific sequences in the external envelope protein of
human immunodeficiency virus type 1 upon primary infection. J Virol
1993, 67:3345-3356.
12. Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA, Ho DD: Genotypic and
phenotypic characterization of HIV-1 patients with primary infection.
Science 1993, 261:1179-1181.
13. Wolinsky SM, Wike CM, Korber BT, Hutto C, Parks WP, Rosenblum LL,
Kunstman KJ, Furtado MR, Munoz JL: Selective transmission of human
immunodeficiency virus type-1 variants from mothers to infants. Science
1992, 255:1134-1137.
14. Dickover RE, Garratty EM, Plaeger S, Bryson YJ: Perinatal transmission of
major, minor, and multiple maternal human immunodeficiency virus
type 1 variants in utero and intrapartum. J Virol 2001, 75:2194-2203.
15. Wu X, Parast AB, Richardson BA, Nduati R, John-Stewart G, Mbori-Ngacha D,
Rainwater SM, Overbaugh J: Neutralization escape variants of human
immunodeficiency virus type 1 are transmitted from mother to infant. J
Virol 2006, 80:835-844.
16. Zhang H, Hoffmann F, He J, He X, Kankasa C, West JT, Mitchell CD,
Ruprecht RM, Orti G, Wood C: Characterization of HIV-1 subtype C
envelope glycoproteins from perinatally infected children with different
courses of disease. Retrovirology 2006, 3:73.
17. Doms RW: Unwelcome guests with master keys: how HIV enters cells
and how it can be stopped. Top HIV Med 2004, 12:100-103.
18. Haaland RE, Hawkins PA, Salazar-Gonzalez J, Johnson A, Tichacek A, Karita E,
Manigart O, Mulenga J, Keele BF, Shaw GM, Hahn BH, Allen SA,
Derdeyn CA, Hunter E: Inflammatory genital infections mitigate a severe
genetic bottleneck in heterosexual transmission of subtype A and C HIV-
1. PLoS Pathog 2009, 5:e1000274.
19. Bhattacharyya D, Brooks BR, Callahan L: Positioning of positively charged
residues in the V3 loop correlates with HIV type 1 syncytium-inducing
phenotype. AIDS Res Hum Retroviruses 1996, 12:83-90.
20. Clevestig P, Pramanik L, Leitner T, Ehrnst A: CCR5 use by human
immunodeficiency virus type 1 is associated closely with the gp120 V3
loop N-linked glycosylation site. J Gen Virol 2006, 87:607-612.
21. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D: Effects of CCR5 and
CD4 cell surface concentrations on infections by macrophagetropic
isolates of human immunodeficiency virus type 1. J Virol 1998,
72:2855-2864.
22. Mascola JR, D’Souza P, Gilbert P, Hahn BH, Haigwood NL, Morris L,
Petropoulos CJ, Polonis VR, Sarzotti M, Montefiori DC: Recommendations
for the design and use of standard virus panels to assess neutralizing
antibody responses elicited by candidate human immunodeficiency
virus type 1 vaccines. J Virol 2005, 79:10103-10107.
23. Montefiori D: Evaluating neutralizing antibodies against HIV, SIV and
SHIV in luciferase reporter gene assays. In Current Protocols in
Immunology. Edited by: Coligan JE, Kruisbeek DH, Margulies EM, Strober W,
Coico R. Hoboken, NJ: John Wiley 2004:12.11.11-12.11.15.
24. Gray ES, Moore PL, Bibollet-Ruche F, Li H, Decker JM, Meyers T, Shaw GM,
Morris L: 4E10-resistant variants in a human immunodeficiency virus
type 1 subtype C-infected individual with an anti-membrane-proximal
external region-neutralizing antibody response. J Virol 2008, 82:2367-2375.
Kishko et al. Retrovirology 2011, 8:67
http://www.retrovirology.com/content/8/1/67
Page 12 of 14
25. Nakamura KJ, Gach JS, Jones L, Semrau K, Walter J, Bibollet-Ruche F,
Decker JM, Heath L, Decker WD, Sinkala M, Kankasa C, Thea D, Mullins J,
Kuhn L, Zwick MB, Aldrovandi GM: 4E10-resistant HIV-1 isolated from four
subjects with rare membrane-proximal external region polymorphisms.
PLoS One 2010, 5:e9786.
26. Sanders RW, Venturi M, Schiffner L, Kalyanaraman R, Katinger H, Lloyd KO,
Kwong PD, Moore JP: The mannose-dependent epitope for neutralizing
antibody 2G12 on human immunodeficiency virus type 1 glycoprotein
gp120. J Virol 2002, 76:7293-7305.
27. Pugach P, Ketas TJ, Michael E, Moore JP: Neutralizing antibody and anti-
retroviral drug sensitivities of HIV-1 isolates resistant to small molecule
CCR5 inhibitors. Virology 2008, 377:401-407.
28. Tilton JC, Amrine-Madsen H, Miamidian JL, Kitrinos KM, Pfaff J, Demarest JF,
Ray N, Jeffrey JL, Labranche CC, Doms RW: HIV type 1 from a patient with
baseline resistance to CCR5 antagonists uses drug-bound receptor for
entry. AIDS Res Hum Retroviruses 2010, 26:13-24.
29. Kliks S, Contag CH, Corliss H, Learn G, Rodrigo A, Wara D, Mullins JI,
Levy JA: Genetic analysis of viral variants selected in transmission of
human immunodeficiency viruses to newborns. AIDS Res Hum Retroviruses
2000, 16:1223-1233.
30. Jordan MR, Kearney M, Palmer S, Shao W, Maldarelli F, Coakley EP,
Chappey C, Wanke C, Coffin JM: Comparison of standard PCR/cloning to
single genome sequencing for analysis of HIV-1 populations. J Virol
Methods 2010, 168:114-120.
31. Derdeyn CA, Hunter E: Viral characteristics of transmitted HIV. Curr Opin
HIV AIDS 2008, 3:16-21.
32. Zhang H, Tully DC, Hoffmann FG, He J, Kankasa C, Wood C: Restricted
genetic diversity of HIV-1 subtype C envelope glycoprotein from
perinatally infected Zambian infants. PLoS One 2010, 5:e9294.
33. Chohan B, Lang D, Sagar M, Korber B, Lavreys L, Richardson B, Overbaugh J:
Selection for human immunodeficiency virus type 1 envelope
glycosylation variants with shorter V1-V2 loop sequences occurs during
transmission of certain genetic subtypes and may impact viral RNA
levels. J Virol 2005, 79:6528-6531.
34. Asjo B, Morfeldt-Manson L, Albert J, Biberfeld G, Karlsson A, Lidman K,
Fenyo EM: Replicative capacity of human immunodeficiency virus from
patients with varying severity of HIV infection. Lancet 1986, 2:660-662.
35. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P,
Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR,
Landau NR: Identification of a major co-receptor for primary isolates of
HIV-1. Nature 1996, 381:661-666.
36. Schuitemaker H, Koot M, Kootstra NA, Dercksen MW, de Goede RE, van
Steenwijk RP, Lange JM, Schattenkerk JK, Miedema F, Tersmette M:
Biological phenotype of human immunodeficiency virus type 1 clones at
different stages of infection: progression of disease is associated with a
shift from monocytotropic to T-cell-tropic virus population. J Virol 1992,
66:1354-1360.
37. Kourtis AP, Bulterys M: Mother-to-child transmission of HIV: pathogenesis,
mechanisms and pathways. Clin Perinatol 2010, 37:721-737, vii.
38. Van de Perre P: Mother-to-child transmission of HIV-1: the ‘all mucosal’
hypothesis as a predominant mechanism of transmission. AIDS 1999,
13:1133-1138.
39. Alexander M, Lynch R, Mulenga J, Allen S, Derdeyn CA, Hunter E: Donor
and recipient envs from heterosexual human immunodeficiency virus
subtype C transmission pairs require high receptor levels for entry. J
Virol 2010, 84:4100-4104.
40. Lee B, Sharron M, Montaner LJ, Weissman D, Doms RW: Quantification of
CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells,
and differentially conditioned monocyte-derived macrophages. Proc Natl
Acad Sci USA 1999, 96:5215-5220.
41. Peters PJ, Duenas-Decamp MJ, Sullivan WM, Clapham PR: Variation of
macrophage tropism among HIV-1 R5 envelopes in brain and other
tissues. J Neuroimmune Pharmacol 2007, 2:32-41.
42. Peters PJ, Sullivan WM, Duenas-Decamp MJ, Bhattacharya J,
Ankghuambom C, Brown R, Luzuriaga K, Bell J, Simmonds P, Ball J,
Clapham PR: Non-macrophage-tropic human immunodeficiency virus
type 1 R5 envelopes predominate in blood, lymph nodes, and semen:
implications for transmission and pathogenesis. J Virol 2006,
80:6324-6332.
43. Isaacman-Beck J, Hermann EA, Yi Y, Ratcliffe SJ, Mulenga J, Allen S,
Hunter E, Derdeyn CA, Collman RG: Heterosexual transmission of human
immunodeficiency virus type 1 subtype C: Macrophage tropism,
alternative coreceptor use, and the molecular anatomy of CCR5
utilization. J Virol 2009, 83:8208-8220.
44. Salazar-Gonzalez JF, Salazar MG, Keele BF, Learn GH, Giorgi EE, Li H,
Decker JM, Wang S, Baalwa J, Kraus MH, Parrish NF, Shaw KS, Guffey MB,
Bar KJ, Davis KL, Ochsenbauer-Jambor C, Kappes JC, Saag MS, Cohen MS,
Mulenga J, Derdeyn CA, Allen S, Hunter E, Markowitz M, Hraber P,
Perelson AS, Bhattacharya T, Haynes BF, Korber BT, Hahn BH: Genetic
identity, biological phenotype, and evolutionary pathways of
transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med
2009, 206:1273-1289.
45. de Witte L, Nabatov A, Geijtenbeek TB: Distinct roles for DC-SIGN
+-dendritic cells and Langerhans cells in HIV-1 transmission. Trends Mol
Med 2008, 14:12-19.
46. Dickover R, Garratty E, Yusim K, Miller C, Korber B, Bryson Y: Role of
maternal autologous neutralizing antibody in selective perinatal
transmission of human immunodeficiency virus type 1 escape variants. J
Virol 2006, 80:6525-6533.
47. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF,
Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH,
Kwong PD, Shaw GM: Antibody neutralization and escape by HIV-1.
Nature 2003, 422:307-312.
48. Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O’Brien WA, Ratner L,
Kappes JC, Shaw GM, Hunter E: Sensitivity of human immunodeficiency
virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor
specificity defined by the V3 loop of gp120. J Virol 2000, 74:8358-8367.
49. Graham FL, Smiley J, Russell WC, Nairn R: Characteristics of a human cell
line transformed by DNA from human adenovirus type 5. J Gen Virol
1977, 36:59-74.
50. Peters PJ, Bhattacharya J, Hibbitts S, Dittmar MT, Simmons G, Bell J,
Simmonds P, Clapham PR: Biological analysis of human
immunodeficiency virus type 1 R5 envelopes amplified from brain and
lymph node tissues of AIDS patients with neuropathology reveals two
distinct tropism phenotypes and identifies envelopes in the brain that
confer an enhanced tropism and fusigenicity for macrophages. J Virol
2004, 78:6915-6926.
51. Saitou N, Nei M: The neighbor-joining method: a new method for
reconstructing phylogenetic trees. Mol Biol Evol 1987, 4:406-425.
52. Kimura M: A simple method for estimating evolutionary rates of base
substitutions through comparative studies of nucleotide sequences. J
Mol Evol 1980, 16:111-120.
53. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X,
Shaw GM, Kappes JC: Emergence of resistant human immunodeficiency
virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.
Antimicrob Agents Chemother 2002, 46:1896-1905.
54. Neumann T, Hagmann I, Lohrengel S, Heil ML, Derdeyn CA, Krausslich HG,
Dittmar MT: T20-insensitive HIV-1 from naive patients exhibits high viral
fitness in a novel dual-color competition assay on primary cells. Virology
2005, 333:251-262.
55. Sakamoto T, Ushijima H, Okitsu S, Suzuki E, Sakai K, Morikawa S, Muller WE:
Establishment of an HIV cell-cell fusion assay by using two genetically
modified HeLa cell lines and reporter gene. J Virol Methods 2003,
114:159-166.
56. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, Voss G,
Goepfert P, Gilbert P, Greene KM, Bilska M, Kothe DL, Salazar-Gonzalez JF,
Wei X, Decker JM, Hahn BH, Montefiori DC: Human immunodeficiency
virus type 1 env clones from acute and early subtype B infections for
standardized assessments of vaccine-elicited neutralizing antibodies. J
Virol 2005, 79:10108-10125.
57. Li M, Salazar-Gonzalez JF, Derdeyn CA, Morris L, Williamson C, Robinson JE,
Decker JM, Li Y, Salazar MG, Polonis VR, Mlisana K, Karim SA, Hong K,
Greene KM, Bilska M, Zhou J, Allen S, Chomba E, Mulenga J, Vwalika C,
Gao F, Zhang M, Korber BT, Hunter E, Hahn BH, Montefiori DC: Genetic and
neutralization properties of subtype C human immunodeficiency virus
type 1 molecular env clones from acute and early heterosexually
acquired infections in Southern Africa. J Virol 2006, 80:11776-11790.
58. Shiu C, Cunningham CK, Greenough T, Muresan P, Sanchez-Merino V,
Carey V, Jackson JB, Ziemniak C, Fox L, Belzer M, Ray SC, Luzuriaga K,
Persaud D: Identification of ongoing human immunodeficiency virus
type 1 (HIV-1) replication in residual viremia during recombinant HIV-1
poxvirus immunizations in patients with clinically undetectable viral
Kishko et al. Retrovirology 2011, 8:67
http://www.retrovirology.com/content/8/1/67
Page 13 of 14
loads on durable suppressive highly active antiretroviral therapy. J Virol
2009, 83:9731-9742.
59. Westby M, Smith-Burchnell C, Mori J, Lewis M, Mosley M, Stockdale M,
Dorr P, Ciaramella G, Perros M: Reduced maximal inhibition in phenotypic
susceptibility assays indicates that viral strains resistant to the CCR5
antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol
2007, 81:2359-2371.
60. Origin Lab Corporation: Origin Scientific Graphing and Analysis Software.
OriginLab Corporation, Northampton, MA; 2003 [http://www.originlab.com].
61. Siegel S, Castellan NJ Jr: Nonparametric Statistics for the Behavioral
Sciences. New York, NY: McGraw-Hill;, 2 1988, 399.
62. SAS Institute Inc: The MIXED Procedure. SAS Institute, Inc., Cary, NC; 1997
[http://www.sas.com].
doi:10.1186/1742-4690-8-67
Cite this article as: Kishko et al.: Genotypic and functional properties of
early infant HIV-1 envelopes. Retrovirology 2011 8:67.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Kishko et al. Retrovirology 2011, 8:67
http://www.retrovirology.com/content/8/1/67
Page 14 of 14
